Coya Therapeutics EBIT

The latest EBIT for COYA is $-2.1B as of June 2026. That compares with $-6.4B in the prior-year period — up 66.8% year over year. That is below the sector sector average of $-9.6M. Investors often review this figure alongside Coya Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, COYA's EBIT moved from $-6.4B to $-2.1B — a 66.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Coya Therapeutics's operating scale or balance-sheet position.

Against its sector companies, COYA currently prints $-2.1B for EBIT, while the sector average sits near $-9.6M. That is roughly 22059.0% below the sector mean. Large gaps often invite a closer look at Coya Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-2.1B for COYA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-9.6M. Explore the charts below for those layers of context.

After noting COYA's EBIT ($-2.1B), review year-over-year change from $-6.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.